Lumen Bioscience lands up to $7M from Department of War for antiviral trial

What's the deal? Seattle-based Lumen Bioscience has been awarded up to $7M from the Department of War to fund Phase 1 clinical development of LMN-1001, a host-directed, investigational intranasal antiviral candidate.

What's the endgame? The grant will support a Phase 1 trial evaluating the safety, tolerability, and pharmacologic activity of LMN-1001 in healthy volunteers. Because it targets the host rather than the virus, the candidate is positioned as a broad countermeasure that could hold up across viral threats.

Why now? The award lands as US biotech competition with China draws federal attention, with Seattle making its case to Washington and the National Security Commission on Emerging Biotechnology convening in the city.

The signal: At $7M, the grant sits in roughly the 92nd percentile of US health grants tracked, underscoring growing defence interest in biotech as a national security asset.

Read more: lifesciencewa.org